Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the safety and effectiveness of cenegermin eye drops to heal persistent corneal epithelial defects PCED, a condition where the cornea does not properly heal. This phase 3 clinical trial compares cenegermin with a placebo vehicle to see how well it induces complete healing after 4 weeks of treatment. The study is conducted across multiple centers with participants randomly assigned to groups, and both participants and researchers do not know who receives which treatment. Participants will receive either cenegermin or a placebo eye drop applied topically to the affected eye. The study includes three periods an initial 8-week treatment phase, followed by an 8-week extension treatment phase for continued evaluation, and finally a 24-week follow-up phase to monitor long-term outcomes. Participants are randomly assigned to one of the two groups, and the treatment is administered throughout these periods. During the study, participants will be regularly assessed to monitor corneal healing and safety. Measurements include the proportion of participants achieving complete healing at 4 and 8 weeks, changes in the size of the corneal defect, and monitoring of any adverse events up to week 40. Study visits and evaluations will track progress and safety over the total study duration, ensuring careful follow-up of all participants.